Introduction
Poliovirus is a member of the picornaviridae and has an icosahedral structure composed of 60 copies of each of four capsid proteins designated VP1, VP2, VP3 and VP4. The three-dimensional structure of both types 1 and 3 poliovirus have been determined (Hogle et al., 1985; Filman et al., 1989) and it has been shown that the amino acid sequences from capsid proteins VP1, VP2 and VP3, but not VP4, are exposed on the surface of infectious virus.
The antigenic structure of types 1 and 3 poliovirus has been analysed by means of the selection of mutant viruses resistant to neutralization by monoclonal antibodies and the resulting amino acid substitutions identified by primer extension sequencing (Minor et al., 1983 (Minor et al., , 1986 (Minor et al., , 1987 Page et al., 1988; Wiegers et al., 1989) . Four antigenic sites have been identified on both types 1 and 3 poliovirus. Some of these sites are complex, comprising amino acid sequences from more than one capsid protein. The sites identified so far are site 1, VP1 residues 89 to 100, 141 to 152, 166 and 253; site 2, VP1 residues 220 to 222, VP2 residues 164 to 172 and VP2 residue 270; site 3, VP3 residues 58 to 60, 70, 71 and VP1 residues 286 to 290; site 4, VP2 residue 72 and VP3 residues 76 to 79. There are differences in immunodominance in BALB/c mice of the different sites for types 1 and 3 poliovirus (Minor et al., 1987) but mutations have not yet been identified in all segments of the complex sites for either type 1 or type 3 virus.
Following infection of tissue culture cells with poliovirus, both infectious and non-infectious virus particles are present in the culture fluid. The non-infectious particles may be immature virions lacking viral RNA or empty capsids formed during the process of attachment and uncoating. On sucrose gradients the two particles sediment at 155S and 80S respectively (FernandezTomas & Baltimore, 1973; Minor et al., 1980) . These particles have been designated D and C antigen respectively (Mayer et al., 1957) . Studies with polyclonal and monoclonal antibodies have shown that, as well as possessing distinct antigenic determinants, the 155S and 80S peaks obtained with type 3 poliovirus also share at least one antigenic determinant Ferguson et al., 1984) .
This paper describes studies with monoclonal antibodies and synthetic peptides which demonstrate that the amino acid sequences of antigenic sites involved in the neutralization of infectious virus are also present on the surface of non-infectious empty particles, but in different configurations.
Methods

Preparation of [3SS]methionine-labelled virus.
The Sabin strains of poliovirus types 1 (P1/LSc), (P2/712ch) and 3 (P3/Leon 12a, b) and antigenic mutants derived from them were grown in HEP2c cells and purified on sucrose gradients as described previously .
Single radial immunodiffusion antigen blocking tests. These were carried out as described previously (Ferguson et al., 1984) . Briefly, dilutions of monoclonal antibody or polyclonal sera were added to wells in agarose gets containing low concentrations of hyperimmune antipoliovirus serum. After the wells had emptied, [3sS]methioninelabelled 155S D antigen or 80S C antigen were added to the wells. Diffusion of radiolabelled antigen in the gel after 24 to 48 h was detected by autoradiography. Test antibody is considered to react with antigen if its diffusion into the gel is inhibited compared with control antigen in a well to which phosphate-buffered saline had been added. Antigen blocking titres are expressed as the dilution of antibody that reduces the zone size by 75% in comparison with zones produced with control antigen.
Preparation of monoclonal antibodies. Monoclonal antibodies were prepared by fusion of splenocytes from immunized BALB/c mice and myeloma cells as described previously (Ferguson et aL, 1984) . Hybridoma supernatants were screened using antigen blocking tests and ascites were prepared in syngeneic mice.
Peptide and polyclonal antipeptide sera. Peptides containing amino acid sequences located at antigenic sites 1, 3a and 3b of type 3 Sabin vaccine virus were synthesized by the Fmoc polyamide method of solidphase peptide synthesis (Cambridge Research Biochemicals; Brown et al., 1983) . The sequences of the peptides were VP1 residues 89 to 104 (designated S10a), VP1 residues 282 to 292 (designated $21) and VP3 residues 53 to 68 (designated $20). An additional peptide, designated W 1, which contains the amino acid sequence from VP2 residues 160 to 174 was kindly synthesized by Wellcome Biotechnology. Rabbit sera were prepared against peptides coupled to carrier protein as described previously .
Results
Antigenic sites recognized by C-specific monoclonal antibodies
Monoclonal antibodies were identified which reacted with D antigen, C antigen or both D and C antigen in antigen blocking tests indicating that the two particles contain both shared and distinct epitopes (Ferguson et al., 1984) . The sites of reactivity of monoclonal antibodies with neutralizing activity were identified by selection of neutralization-resistant mutants or by neutralization of viruses with amino acid substitutions identified by primer extension sequencing. However only one out of 29 C-specific antibodies blocked the production of cytopathic effect. This antibody appeared to be directed against site 1, VP1 89 to 100 (Minor et al., 1986) .
The remaining 28 C-specific antibodies were tested in antigen blocking tests with the 80S peak of representative mutants with amino acid substitutions in each of the antigenic sites. Eight of the 28 antibodies tested failed to react with at least one virus with an amino acid substitution in an antigenic site. The results obtained with these antibodies are shown in Table 1 . Antibodies 516 and 518 did not react with virus strains 4008 and 4025 which had amino acid substitutions at residues 166 and 164 on VP2 respectively. They did however react with virus 4023 which has a mutation at residue 172 of VP2. This suggests that these antibodies are directed against antigenic site 2 and that, as with the neutralizing D-or D + C-reactive antibodies, not all mutations within an antigenic site will affect the reactivity of individual antibodies. Similarly, antibodies 131 and 468 failed to react with virus 4022 which has a mutation in site 3b at VP3 residue 59, indicating that they are directed against site 3b. Antibodies 182 and 475 did not react with virus strains 4030 or 4031 which have mutations in site 4 at VP3 residues 77 and 79 respectively. However antibodies 209 and 212 reacted with virus 4030 but not 4031. The four main antigenic sites involved in neutralization of infectious virus are therefore also present on the surface of non-infectious C antigen but in a different configuration.
All C antigen-specific antibodies were tested for reactivity with separated poliovirus capsid proteins in immunoblot experiments. Four antibodies were found to react with VP1 and one with VP3 (Ferguson et al., 1984) , but none of these antibodies were found to be directed against antigenic sites in the studies described above. The lack of reactivity in immunoblots of antibodies directed against the antigenic sites on non-infectious C antigen particles indicates that the surface features of empty particles, like those of infectious virus, have a defined structure. Further information on the site of reactivity of the unassigned C-specific antibodies may be obtained when chimeric polioviruses, in which sequences of eight to 10 amino acids from type 3 virus are inserted into the homologous region on type 1 virus, become available.
Reactivity of monoclonal antibodies with the antigenic sites of type 3 poliovirus D and C antigen
A total of 83 monoclonal antibodies against type 3 poliovirus have been characterized with respect to reactivity with D and C antigens. The antigenic sites which have been identified so far for type 3 virus are given in Table 2 along with the number of antibodies which have been identified as directed against each site on D and/or C antigen. The antigenic sites against which three out of 45 D-specific antibodies are directed have yet to be identified whereas 20 of the 29 C-specific antibodies have still to be assigned to antigenic sites. Five out of nine antibodies which react with both D and C antigens are directed against site 1 at VP1 residues 89 to 100 indicating that at least part of this loop is in the same configuration on both particles. In contrast, no D-and Creactive antibodies directed against sites 3 or 4 have been identified. However only one antibody against site 4 on D antigen has been produced suggesting that this site on infectious virus is not well recognized by the mouse immune system. An antibody designated 200 reacted with both D and C antigens in antigen blocking tests. This antibody neutralized virus in standard microtitre assays but no mutant viruses could be isolated as the titre was reduced by only 90 % in plaque reduction assays. This antibody is * Sequence: VP1 residues 282-292, (C)GVDYRNNLDPLC. 1" Sequence: VP2 residues 160-174, (C)FNKDNAVTSPKREFC.
thought to be directed against site 2 on the basis of its failure to react in antigen blocking tests with a strain, DM 35, excreted by a primary vaccinee. The entire capsid region of this strain has been sequenced and the only amino acid substitution found which maps at the surface of the virus was in site 2 on VP2 at residue 165 (A. Macadam, personal communication). In addition, although this antibody reacted with D antigen of site 2 mutants 4008 and 4025 which have amino acid substitutions in VP2 at residues 166 and 164 respectively (see Table 1 ), it failed to react with C antigen of these viruses in antigen blocking tests. This suggests that the change in configuration caused by the amino acid substitutions was greater in the empty C antigen particles than in the infectious D antigen particles.
Reactivity of antipeptide sera with poliovirus particles
Antisera which were prepared against synthetic peptides comprising amino acid sequences of antigenic site 1 (peptide S10a), site 2b (peptide W1), site 3a (peptide $21) and site 3b (peptide $20) were tested in antigen blocking tests with type 3 D and C antigens. Sera from animals immunized with site 1 peptide S10a developed antibodies to both D and C antigens whereas no antiviral activity was obtained with site 3b peptide $20. Site 2 peptide W 1 induced antibodies which recognized both D and C antigens in antigen blocking tests (Table 3 ) whereas antisera to site 3a peptide S21 reacted only with C antigen suggesting that the peptide adopted the configuration found on C but not D antigen. The data for site 3a confirm that this sequence is at the surface of empty C antigen particles but in a configuration different to that found on D antigen.
Discussion
Although the structure of infectious type 3 poliovirus is well defined both at the atomic (Filman et al., 1989) and antigenic (Minor et al., 1986 ) levels, little is known about the structure and antigenic proper!ies of empty C antigen particles. Monoclonal antibodies produced against type 3 poliovirus antigens were initially used to characterize the antigenic structure of infectious virus, D antigen and non-infectious empty C antigen particles. Antibodies were identified which reacted with D antigen, C antigen or both D and C antigen indicating that the two particles contain both shared and distinct epitopes (Ferguson et al., 1984) . In these studies we show that the amino acid sequences which form the main antigenic sites on type 3 virus are also exposed on the surface of empty C antigen particles but in different configurations. This conclusion is supported by the reactions of antisera raised with synthetic peptides. The panel of type 3 monoclonal antibodies used in these studies was the product of several fusions in which different viruses and particles were used as immunogens and for screening and do not therefore reflect the relative dominance of the different sites. It is of interest that the majority of D + C-reactive antibodies are directed against site 1 suggesting that less conformational change takes place within this exposed loop when RNA is lost. However there are also a large number of D-specific antibodies directed against this site (Ferguson et al., 1984) indicating that some regions are in different configurations. There does not appear to be a clear distinction between amino acids recognized by D-or D + C-reactive antibodies from studies involving the reactivity of monoclonal antibodies with variant viruses containing single amino acid substitutions within site 1 (P. D. Minor, unpublished data).
Monoclonal antibodies against the complex antigenic sites 2, 3 and 4 are D-or C-reactive with the exception of antibody 200. Three polypeptide segments from type 1 virus contribute to antigenic site 2 although only two have so far been identified on type 3 virus. The complex nature of this site may therefore be responsible for the unusual binding properties of antibody 200 in that different mutations may result in different local conformational changes on D and C antigens.
The two segments of antigenic site 3 appear to be in different configurations on D and C antigen particles on the basis of reactivity with monoclonal antibodies and with an antiserum against a peptide corresponding to residues 286 to 290 on VP1. That the antipeptide serum reacted only with empty C antigen particles demonstrates the problems of using peptides as a synthetic vaccine for antigens with a defined structure.
The studies described here provide information on the surface features of non-infectious type 3 C antigen particles and on the structure of type 3 poliovirus. The antibodies used in these studies may be useful tools for investigating the structural transitions which occur during adsorption to cells, uncoating, viral assembly and during thermal inactivation.
